14q22q23 microdeletion syndrome is a rare genetic condition caused by a small missing piece of chromosome 14. People with 14q22q23 microdeletion syndrome often have eye or vision differences, distinctive facial features, and differences in limb or hand development. Many living with 14q22q23 microdeletion syndrome also have feeding challenges in infancy, growth differences, and learning or developmental delays that can range from mild to more significant. The condition is lifelong, usually recognized in infancy or early childhood, and severity can vary. Care focuses on supportive therapies, vision and hearing care, surgeries when needed, and developmental, educational, and family support, and the outlook depends on the features present.
Overview
14q22q23 microdeletion syndromeSymptoms
Early signs of 14q22q23 microdeletion syndrome are seen at birth or early childhood: small or missing eyes, vision loss, hearing problems, feeding difficulty, low muscle tone, and slow growth. Other features include hormonal (pituitary) issues, limb differences, and developmental delays.
Outlook and prognosis
Many people with 14q22q23 microdeletion syndrome grow and learn at their own pace, often needing ongoing therapies and school supports. Hearing, vision, and hormone issues may require specialist care over time. With coordinated care and early intervention, skills and independence can improve.
Causes and risk factors
14q22q23 microdeletion syndrome results from a small missing segment on chromosome 14, typically arising de novo before birth. Rarely, it’s inherited from an affected parent or due to a parent’s balanced rearrangement; lifestyle or environmental risks aren’t established.
Genetic influences
Genetics are central to 14q22q23 microdeletion syndrome because the condition results from missing DNA on chromosome 14. The size and exact genes deleted can shape severity and features. Most cases are not inherited, but parental testing clarifies recurrence risk.
Diagnosis
Clinicians suspect 14q22q23 microdeletion syndrome from characteristic developmental and eye or brain features. Genetic testing—usually chromosomal microarray or targeted deletion analysis—confirms it. Imaging of the brain, eyes, or pituitary can support the genetic diagnosis of 14q22q23 microdeletion syndrome.
Treatment and drugs
Treatment for 14q22q23 microdeletion syndrome focuses on each person’s needs, often blending early therapies, vision and hearing support, feeding help, and educational plans. Specialists may guide hormone or growth concerns, bone and joint care, and seizure management if needed. Regular check-ins help adjust therapies as children grow.
Symptoms
Many families first notice eye differences, feeding challenges, or slow growth. 14q22q23 microdeletion syndrome is present from birth and tends to affect eye development, hormone control from the pituitary gland, growth, and learning. Early on, this might look like vision changes, low blood sugar, or trouble gaining weight—the early features of 14q22q23 microdeletion syndrome. Not everyone has the same set of features, and their impact can range from mild to more complex.
Many babies are born with small or missing eyes; this is known medically as microphthalmia or anophthalmia. Vision may be reduced or absent. Eyelids and eye muscles may also be affected, such as droopy lids.
The pituitary gland may not make enough hormones. This can cause low blood sugar in newborns, slow growth, low thyroid levels, or delayed puberty. In 14q22q23 microdeletion syndrome, ongoing hormone testing and treatment are often part of care.
Children may grow more slowly than peers, leading to shorter height over time. After testing, growth hormone therapy may be recommended.
Newborns may have trouble latching or swallowing and may tire easily during feeds. Reflux and poor weight gain can follow. Feeding therapy or temporary tube feeding can help in infancy.
How people usually first notice 14q22q23 microdeletion syndrome?
Families often first notice 14q22q23 microdeletion syndrome in infancy when a baby has feeding difficulties, poor weight gain, or low muscle tone, and doctors may see distinctive facial features or eye differences during early checkups. Some babies are identified before or shortly after birth because ultrasounds or newborn exams reveal limb differences (especially missing or shortened radius/thumb), underdeveloped or asymmetrical eyes, or concerns about the pituitary gland that can affect growth and blood sugar. For many, the first signs of 14q22q23 microdeletion syndrome become clearer in the first year through delayed motor milestones and small size for age, prompting genetic testing to confirm the diagnosis.
Types of 14q22q23 microdeletion syndrome
14q22q23 microdeletion syndrome is a genetic condition caused by a small missing segment on chromosome 14 that typically involves key genes for eye, pituitary, and limb development. Clinicians often describe them in these categories: recurrent, well-mapped microdeletions versus atypical or larger deletions that extend beyond the core region. These variants can lead to differences in which features are present and how severe they are, from eye structure differences to growth hormone problems. Understanding the types of 14q22q23 microdeletion syndrome can help explain why symptoms vary among individuals.
Core-region deletion
This involves the commonly affected band at 14q22–q23, often including genes tied to eye, pituitary, and limb development. People may have eye differences, short stature from pituitary hormone issues, and limb or hand/foot changes.
Extended deletion
The missing segment stretches beyond the typical 14q22–q23 interval into nearby regions. Symptoms may be broader, with more learning differences or additional organ findings along with the core features.
Small atypical deletion
Only part of the usual region is missing, sometimes sparing one or more key genes. Features can be milder or more selective, such as eye findings without hormone-related growth issues, or the reverse.
Gene-specific disruption
The deletion clearly removes a single critical gene within 14q22–q23. Symptoms often reflect that gene’s role, which can narrow the pattern—for example, stronger effects on eye formation or pituitary function.
Mosaic deletion
The deletion is present in some cells but not others. Intensity can range from subtle findings to near-typical presentations, depending on how many cells carry the change.
Familial versus de novo
Some deletions are inherited, while many arise as new changes. Inherited forms may show similar patterns within a family, whereas de novo cases vary widely in features and severity.
What genetics can tell you about symptoms
Some people with 14q22q23 microdeletion syndrome have smaller eyes or missing eye structures, underdeveloped pituitary glands causing growth or hormone problems, and distinctive facial features; these track to losses near genes like OTX2, BMP4, and SIX6. Deletions affecting OTX2 often relate to eye and pituitary issues, while BMP4 loss can connect with limb, tooth, or kidney differences.
Causes and risk factors
In 14q22q23 microdeletion syndrome, a small piece of chromosome 14 is missing. This usually happens by chance in the egg or sperm, but it can sometimes be inherited from a parent who carries the same change. Family history is the main risk factor for 14q22q23 microdeletion syndrome, and future pregnancies have higher chances if a parent carries it. Prenatal health, nutrition, and early therapies do not cause the deletion, but they can influence how strongly features show. Genetic testing can sometimes clarify your personal risk.
Environmental and biological risk factors
For 14q22q23 microdeletion syndrome, risk comes from changes that happen very early in reproduction rather than anything during pregnancy. Most cases happen by chance when an egg or sperm is forming, not because of anything parents did. Doctors often group risks into internal (biological) and external (environmental). Below we outline environmental and biological risk factors for 14q22q23 microdeletion syndrome in plain language.
Many cases start with a one-time DNA change as an egg or sperm forms. This copying mistake can delete a small stretch of chromosome 14. This is the most common way 14q22q23 microdeletion syndrome begins.
Fathers at older ages have a higher rate of new DNA changes in sperm. This may modestly raise the chance of structural changes like a small deletion. The overall risk for any single pregnancy remains low.
Significant ionizing radiation to either parent before conception can damage reproductive cells. Such damage can increase the likelihood of chromosome breaks that lead to deletions, the underlying change in 14q22q23 microdeletion syndrome. Routine diagnostic imaging uses much lower doses and is not known to raise this risk.
Some chemotherapy and pelvic radiation can harm eggs or sperm and increase DNA damage. If exposure occurs before conception, this may raise the chance of chromosome changes, including deletions. Care teams often recommend a recovery interval before trying for pregnancy.
Genetic risk factors
Genetic risk factors for 14q22q23 microdeletion syndrome center on small missing segments on chromosome 14q22–q23 that remove key eye and brain‑development genes such as OTX2 and BMP4. Risk is not destiny—it varies widely between individuals. Most deletions arise as new events, but some are inherited or can recur because of a hidden rearrangement or mosaicism in a parent. Understanding the genetic causes of 14q22q23 microdeletion syndrome can guide testing and family planning.
14q22–q23 deletion: A small missing piece on the long arm of chromosome 14 in the q22–q23 region is the core cause. Losing one working copy of genes here can disrupt early eye, brain, and facial development. This missing DNA drives the condition’s main features.
OTX2 gene: Loss of one OTX2 copy is strongly linked to small or missing eyes and pituitary differences. It can lead to hormone shortages that affect growth, feeding, and energy in infancy. OTX2 changes help explain many early symptoms of 14q22q23 microdeletion syndrome.
BMP4 gene: Deleting one copy of BMP4 can contribute to eye, facial, tooth, or limb differences. Its effects depend on which neighboring genes are also missing. When BMP4 stays intact, features may be milder even with a nearby deletion.
SIX6 gene: Missing SIX6 may add to eye‑development differences and vision problems. On its own it can be subtle, but alongside OTX2 or BMP4 loss it can increase severity.
Deletion size: The size of the deletion shapes which genes are lost and which body systems are affected. Larger deletions tend to cause a broader range of features, while smaller ones may be more focused. This size–effect relationship helps explain why people’s experiences vary.
De novo cases: In many families, the deletion happens as a brand‑new event in the egg or sperm, with parents’ blood tests appearing normal. This usually means a low chance of it happening again, though a small residual risk remains due to hidden mosaicism. In some cases, genetic testing can give a clearer picture of your personal risk.
Dominant inheritance: If a parent carries the same deletion, it can pass to children in an autosomal dominant pattern. Each pregnancy has about a 50% chance to inherit the deletion, though the features can differ in severity.
Balanced rearrangement: A parent can have a balanced chromosome change involving 14q22–q23 and be healthy. Such a rearrangement raises the chance of a child inheriting an unbalanced form that includes the deletion.
Parental mosaicism: Rarely, a parent carries the deletion in a mosaic form limited to some eggs or sperm. This hidden pattern can raise recurrence risk even when routine blood testing is normal. Exploring your family’s health background is a valuable starting point.
Variable effects: The same deletion can lead to a wide range of features, from mild learning needs to complex medical care. People with the same risk factor can have very different experiences.
Lifestyle risk factors
This is a genetic/congenital condition; lifestyle habits do not cause it, but day-to-day choices can influence growth, mobility, learning, and the risk of complications. Understanding how lifestyle affects 14q22q23 microdeletion syndrome helps families prioritize routines that support medical care. The elements below focus on behaviors that can ease symptoms or reduce secondary problems over time. Diet and activity are included where they directly relate to typical features of this syndrome.
Nutrient-dense meals support growth and bone health that may be challenged by pituitary hormone deficiencies. Excess calories and sugary drinks can worsen weight gain risks when hormones are out of balance.
Regular, guided movement strengthens core and postural control that can be delayed by hypotonia or limb differences. Weight-bearing play and low-impact exercise help protect bone density if growth hormone is low.
A steady sleep schedule improves daytime attention and behavior, supporting therapy progress for developmental delays. Poor sleep can aggravate irritability and learning challenges common in neurodevelopmental conditions.
Safe feeding techniques and pacing reduce choking and aspiration risk when oral-motor coordination is affected. High-calorie, high-protein options can help meet growth targets despite limited intake.
Risk prevention
14q22q23 microdeletion syndrome is a genetic condition present from conception, so there’s no way to fully prevent it. Prevention focuses on lowering the chance of complications, spotting issues early, and supporting healthy development over time. Even if you can’t remove all risks, prevention can reduce their impact. Plans vary by family and by the child’s specific features, and a coordinated care team can make day-to-day life safer and easier.
A genetics team can explain recurrence risk, offer parental testing to see if the deletion is inherited or new, and outline options. This helps families plan future pregnancies with clearer information.
If a parental change is found, preimplantation genetic testing (PGT) and targeted prenatal testing (CVS or amniocentesis) may be available. Detailed ultrasounds can also look for eye or brain differences linked to 14q22q23 microdeletion syndrome.
Watching for early symptoms of 14q22q23 microdeletion syndrome—such as feeding trouble, low blood sugars, slow growth, or eye differences—can speed referrals. Fast evaluation can prevent avoidable complications.
Early eye exams can protect any remaining vision and guide treatment or protective eyewear. Low-vision services help with learning, mobility, and safety at home and school.
Transmission
14q22q23 microdeletion syndrome is not contagious—you can’t catch it or pass it by contact. It occurs when a small piece of chromosome 14 is missing; in most families, this happens as a new change at conception.
Less often, 14q22q23 microdeletion syndrome is inherited from a parent who also has the deletion, typically in an autosomal dominant pattern, which means each child has a 50% chance of inheriting it. If the change is new in the child, the chance of it happening again is usually low, and genetic counseling with parental testing can clarify the genetic transmission of 14q22q23 microdeletion syndrome.
When to test your genes
14q22q23 microdeletion syndrome is genetic, so consider testing when a child shows early signs like vision or hearing differences, limb or pituitary anomalies, developmental delays, or distinctive facial features. Test if a close relative is affected or a parent carries a balanced rearrangement. Prenatal testing is reasonable when ultrasound suggests related structural findings.
Diagnosis
Parents may first notice feeding difficulties, slower growth, or vision concerns in a child, prompting a check-up. Getting a diagnosis is often a turning point toward answers and support. For 14q22q23 microdeletion syndrome, clinicians look for a pattern of features and then confirm it with genetic tests. In practice, the genetic diagnosis of 14q22q23 microdeletion syndrome relies on chromosomal microarray or similar methods.
The provider looks for a recognizable pattern such as distinctive facial features, growth differences, and eye findings. These clinical features help point toward 14q22q23 microdeletion syndrome.
Speech, motor, and learning skills are checked using age-appropriate tools. This documents strengths and delays that commonly occur with 14q22q23 microdeletion syndrome.
A pediatric eye exam checks for structural differences and vision problems that are common in this condition. These findings can support the suspected diagnosis and guide care.
Newborn or pediatric hearing checks look for hearing loss that may accompany the syndrome. Early results help tailor therapies such as speech and hearing support.
Stages of 14q22q23 microdeletion syndrome
14q22q23 microdeletion syndrome does not have defined progression stages. It’s a chromosome change present from birth, and features can vary a lot from person to person; they’re usually found through targeted checks—like vision, hormone, hearing, and growth evaluations—rather than a steady, predictable decline. Diagnosis is typically made with a chromosomal microarray or similar genetic test alongside a clinical exam that reviews early symptoms of 14q22q23 microdeletion syndrome. Genetic testing may be offered to clarify certain risks.
Outlook and prognosis
Looking ahead can feel daunting, but most children with 14q22q23 microdeletion syndrome make progress over time with steady therapies and medical follow-up. Developmental delays and learning differences are common, and early symptoms of 14q22q23 microdeletion syndrome often include feeding difficulties, low muscle tone, or vision and hearing issues. Some kids also have differences in the eyes, pituitary gland, or limbs that may need specialist care and sometimes surgery. Doctors call this the prognosis—a medical word for likely outcomes.
The outlook is not the same for everyone, but many living with 14q22q23 microdeletion syndrome gain new skills year by year, especially with speech, physical, and occupational therapy. When hormone production is affected, timely treatment can support growth, energy, and bone health, which can improve day-to-day function. Vision or hearing supports, such as glasses, patching, or hearing aids, can also make a noticeable difference in learning and communication. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle.
Serious, life-threatening complications are not the norm, and current reports suggest life expectancy can be near typical when major organ problems are not present and medical needs are addressed. Still, seizures, breathing issues, or feeding challenges can occur in some people and may require long-term follow-up. With ongoing care, many people maintain better health and independence than early testing might suggest. Talk with your doctor about what your personal outlook might look like.
Long-term effects
For many living with 14q22q23 microdeletion syndrome, the long-term picture often centers on growth, vision, and hormone health that can shape school, work, and daily independence. Long-term effects vary widely, and not everyone will have the same combination or severity. Features can shift with age—feeding and muscle tone in infancy may give way to learning differences, vision needs, or hormone changes in adolescence and adulthood. Families sometimes remember early symptoms of 14q22q23 microdeletion syndrome in babyhood, while later years bring more stable patterns that are followed over time.
Many have below-average height related to growth hormone changes in 14q22q23 microdeletion syndrome. Growth may slow in later childhood, with adult height often remaining shorter than peers.
The pituitary gland can be underactive, affecting puberty, thyroid, adrenal function, and fluid balance. Some hormone needs appear later in life and can evolve over time. Doctors may track these changes over years to see how they affect energy, growth, and metabolism.
Eye development can be affected, ranging from reduced vision to severe impairment in one or both eyes. Depth perception, light sensitivity, and reading endurance may be impacted across the lifespan.
Developmental delays and learning differences can persist into adulthood. For some with 14q22q23 microdeletion syndrome, thinking skills, attention, and problem solving may be mildly to moderately affected.
How is it to live with 14q22q23 microdeletion syndrome?
Living with 14q22q23 microdeletion syndrome often means navigating a mix of developmental differences, learning needs, and medical follow-up, with supports tailored to speech, movement, vision, and hearing. Daily life may involve regular therapies, educational accommodations, and appointments with specialists; many families build predictable routines and use adaptive tools to help communication and independence grow over time. People around the individual—parents, siblings, teachers, and friends—often become part of a coordinated care circle, and with clear communication and patience, they can help reduce frustration, celebrate progress, and support inclusion in school and community activities. While challenges are real, early interventions and a steady, team-based approach can make day-to-day life more manageable and meaningful.
Treatment and drugs
Treatment for 14q22q23 microdeletion syndrome focuses on easing symptoms, supporting development, and preventing complications, since there’s no single cure. Care usually involves a team: early intervention with physical, occupational, and speech therapy; hearing and vision care; feeding support if swallowing is difficult; and tailored educational plans as children grow. Surgeons may address cleft palate, limb differences, or other structural issues, while endocrinology can help manage growth or hormone concerns if they arise. Medicines that ease symptoms are called supportive or symptomatic treatments, and may include pain relief after procedures, reflux medications, or therapies for sleep and behavioral challenges when needed. Not every treatment works the same way for every person, so your doctor can help adjust the plan over time based on your child’s needs.
Non-drug treatment
Daily life can be affected by vision, hearing, feeding, and growth challenges. Recognizing early symptoms of 14q22q23 microdeletion syndrome can help families start supportive care sooner. Non-drug treatments often lay the foundation for development and independence. Care is usually coordinated by a multidisciplinary team.
Coordinated therapies in infancy support motor, communication, and social skills. Structured programs, like state early-intervention services, can help build core skills.
Improves strength, balance, and coordination for sitting, standing, and walking. Simple home exercises help maintain progress between visits.
Builds fine-motor skills for feeding, dressing, and play. Therapists adapt tools and environments to boost independence.
Supports language development and safe swallowing. Therapists address oral-motor skills and may introduce alternative communication if speech is delayed.
Your genes may have an impact on how drugs work for you
Medicines for 14q22q23 microdeletion syndrome can work differently because genes involved in brain development, hormone signaling, and metabolism may change how the body processes or responds to drugs. Pharmacogenetic testing and careful dose adjustments help tailor safer, more effective treatment.
Pharmacological treatments
There’s no single “cure,” so medications for 14q22q23 microdeletion syndrome aim to replace missing hormones and manage features like seizures or fluid balance. Drugs that target symptoms directly are called symptomatic treatments. Plans are individualized based on which glands and systems are affected, and they change as children grow. Your team will check labs and growth, then adjust medicines over time to keep levels in a healthy range.
Somatropin can help when the pituitary makes too little growth hormone. In 14q22q23 microdeletion syndrome, this often supports height gain, muscle mass, and energy. Dosing and goals are guided by growth charts and IGF‑1 levels.
Levothyroxine treats central hypothyroidism and supports energy, temperature control, and growth. Doctors typically monitor free T4 (not just TSH) to fine‑tune the dose.
Hydrocortisone replaces cortisol when adrenal signals are low, helping with fatigue, low blood pressure, or illness stress. Families are taught stress‑dosing and when to use an emergency injection during fever, vomiting, or injury.
Estradiol with progesterone (for girls) or testosterone (for boys) may be used if puberty is delayed or absent. Treatment starts low and increases gradually to build age‑appropriate development and bone health.
Genetic influences
14q22q23 microdeletion syndrome happens when a very small piece is missing from chromosome 14—specifically the q22 to q23 region—leaving only one working copy of several genes that guide early development. Understanding whether a condition is inherited can guide next steps. In many families the deletion arises for the first time in the child (not inherited), but it can also be passed on when a parent carries the same deletion or has a balanced chromosome change; in that situation, each child has a chance of inheriting it. The exact features depend on which genes are lost and the size of the missing segment, so effects on eye formation, the pituitary gland, facial shape, and growth can vary widely, even among relatives. If both parents test negative for the deletion, the chance of it happening again in a future pregnancy is usually low, though a small risk remains because of rare mosaic changes in egg or sperm cells. Chromosomal microarray and related tests can detect the 14q22q23 deletion, help estimate recurrence risk, and, because these genes influence early development, early symptoms of 14q22q23 microdeletion syndrome often prompt testing.
Is 14q22q23 microdeletion syndrome genetic?
Genetics are central to 14q22q23 microdeletion syndrome because the condition results from missing DNA on chromosome 14. The size and exact genes deleted can shape severity and features. Most cases are not inherited, but parental testing clarifies recurrence risk.
Pharmacogenetics—how genetics influence drug effects
Medication choices for 14q22q23 microdeletion syndrome often center on hormone replacement, support for vision or hearing, and, for some, anti-seizure therapy. How your body handles certain medicines can be shaped by your genes, which is especially relevant for drugs sometimes used in this condition’s care. For example, pain relievers like codeine or tramadol may be too strong or not effective in people who process these drugs unusually quickly or slowly, so your care team may choose a different option or adjust the dose. Several anti-seizure medicines have well-established genetic safety checks that can lower the risk of rare but serious skin reactions, and some antidepressants or sleep-related medicines may need dose tweaks based on common drug‑processing genes. Alongside medical history and current medications, genetic testing can help predict how you may handle specific drugs. In contrast, dosing for hormone replacement (such as levothyroxine, hydrocortisone, or growth hormone) is usually guided by blood tests and how you feel rather than by pharmacogenetic results. If testing is considered, results are combined with age, body size, and liver and kidney function to tailor treatment for people with 14q22q23 microdeletion syndrome.
Interactions with other conditions
People living with 14q22q23 microdeletion syndrome often have health needs that interact with other conditions, especially those affecting hormones, vision, hearing, and breathing. Doctors call it a “comorbidity” when two conditions occur together. Pituitary hormone problems can change how the body handles stress from infections, injuries, or surgery; if cortisol or thyroid levels are low, even a routine illness may hit harder and recovery can be slower. Craniofacial differences can raise the risk of ear infections and sleep apnea, which may worsen daytime fatigue, learning, and behavior—issues that can be misread as purely developmental. Vision and hearing loss can overlap with attention or social-communication challenges, so teams often reassess to be sure support targets the right cause. Early symptoms of 14q22q23 microdeletion syndrome—such as poor feeding, slow growth, or low energy—may be mistaken for isolated problems like reflux or thyroid disease, so coordinated care helps spot when one condition is amplifying another.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described children who grew more slowly, had small eyes or vision differences, and later needed support with learning and speech. Families and communities once noticed patterns—relatives with similar facial features or shorter height—without knowing there was a shared cause. Doctors wrote scattered case notes about eye structure changes, differences in the pituitary area of the brain, and delayed puberty, but these reports seemed unrelated at the time.
As medical science evolved, chromosome studies offered the first clues. Early karyotypes, which are broad chromosome pictures, often looked normal. It wasn’t until higher‑resolution methods arrived—first targeted tests for chromosomal “missing pieces,” then microarray testing—that a recurring, small deletion on chromosome 14 began to stand out. From these first observations, clinicians linked a cluster of findings: eye development differences, features tied to pituitary hormone shortages, distinctive facial traits, and growth patterns. This constellation was eventually grouped under a single name: 14q22q23 microdeletion syndrome.
In recent decades, knowledge has built on a long tradition of observation. Researchers mapped the commonly deleted stretch more precisely and noted that several genes within this region are especially important for early eye and midline brain development. With each decade, case series expanded from isolated reports to international cohorts, showing that the syndrome can range from mild vision issues and short stature to more complex combinations of eye, hormone, and developmental needs. Not every early description was complete, yet together they built the foundation of today’s knowledge.
Genetic testing changed care as well as naming. Once considered rare, now recognized as part of the modern differential for babies with small eyes (microphthalmia) or children with combined vision and growth‑hormone concerns, the condition moved from obscurity to a clearer diagnostic pathway. Families began to receive more precise explanations for previously puzzling combinations of symptoms, and clinicians could anticipate medical checks—like regular eye exams and hormone evaluations—earlier in life.
Today, the history of 14q22q23 microdeletion syndrome reflects the broader story of genetics moving from single clinical clues to detailed chromosome and gene‑level answers. Looking back helps explain why people with similar features once received different labels, and why current care is more coordinated. As testing continues to improve, the historical arc—from scattered case notes to a defined syndrome—guides earlier recognition and more tailored support for those living with 14q22q23 microdeletion syndrome.